CLINICAL LEARNING GUIDE

P21

P021 | CNTF-Derived Neurotrophic Peptide | LIF-Inhibition / BDNF Pathway

Mechanisms, Evidence, and Clinical Applications

Based on lecture materials by William Seeds, MD — SSRP Institute | *Cellular Medicine Education*

For educational and research purposes only. Not medical advice. P21 (P021) is a PRECLINICAL-STAGE research compound: it is NOT FDA-approved, has had NO human clinical trials of any kind, and has no established human dose, pharmacokinetics, or safety profile. All evidence is from rodent and in-vitro models. Dr. Seeds explicitly recommends AGAINST current human/clinical use of P21. Consult qualified healthcare providers; nothing here should be taken as endorsement of use.

SECTION 1 · PROFILE OF THE PEPTIDE

Overview

P21 (more precisely P021) is a small synthetic neurotrophic peptide derived from ciliary neurotrophic factor (CNTF). It corresponds to CNTF residues 148–151 with an added adamantylated glycine (sequence Ac-DGGLAG-NH_2; MW 578.3 Da), and was developed by Dr. Khalid Iqbal at the New York State Institute for Basic Research. The adamantyl group is the key engineering feature: it increases lipophilicity and gastrointestinal stability, enhancing both oral delivery and blood-brain-barrier penetration. Phanes Biotech is developing P021 for Alzheimer's disease, but it remains at the preclinical/IND stage with no IND or NDA filed as of 2024.

The central design idea is elegant: capture CNTF's neurotrophic, pro-neurogenic benefit while avoiding CNTF's toxicity. Full-length CNTF was trialed in humans (for ALS and obesity) but was limited by serious side effects — anorexia, skeletal-muscle loss, cramps, nausea, and hyperalgesia — driven by activation of the IL6Rα–LIFRβ–gp130 receptor complex. P21 does NOT bind the CNTF receptor (CNTFRα) directly and does NOT activate that complex; instead it appears to act largely by competitively inhibiting leukemia inhibitory factor (LIF) signaling and by upregulating BDNF. In rodents it produced none of the CNTF side effects across long-duration dosing.

P21 occupies an unusual position the practitioner must hold in full. Its preclinical story is broad, consistent, and at times striking — reduced tau and amyloid, a roughly 4-fold increase in neurogenesis, restored cognition across several disease models, prevention of retinal (AMD-like) pathology, and a large survival benefit in Alzheimer mice — yet there are zero human trials, no established human dose, pharmacokinetics, or safety data, at least one notable in-vivo failure (a CDKL5-deficiency model), and a mechanism that is still only partly defined. Dr. Seeds is direct that this is a peptide to learn from but not yet to use: he explicitly recommends against current human experimentation with it. Promising preclinical breadth is not the same as human readiness, and that gap is the central thing to convey.

Peptide Profile

Property	Detail
Name	P21 / P021 (CNTF-derived neurotrophic peptide)
Sequence / MW	Ac-DGGLAG-NH_2; from CNTF residues 148–151 + adamantylated glycine; MW 578.3 Da

Property	Detail
Origin / developer	Derived from ciliary neurotrophic factor; developed by Dr. Khalid Iqbal (NYSIBR)
Development stage	PRECLINICAL only; Phanes Biotech developing for AD; no IND/NDA filed (as of 2024)
Proposed mechanism	Competitive LIF inhibition + BDNF upregulation; does NOT bind CNTFRα; does NOT activate IL6Rα–LIFRβ–gp130
Routes (rodent)	Oral (in diet), oral gavage, subcutaneous pellets; crosses the placental barrier
PK (rodent)	Plasma t½ >3 h (mice); >90% gastric and 100% intestinal stability in vitro; BBB inferred, not directly measured
Human PK/dose	NONE — no human pharmacokinetics, no established human dose, BBB not directly quantified
Human trials	ZERO — no Phase I/II/III studies completed
Regulatory	NOT FDA-approved; preclinical research compound; human safety unknown

Where P21 Sits

Within the neuroprotection group, P21 is a true neurotrophic-mimetic peptide — small, orally and CNS-penetrant, and aimed squarely at endogenous BDNF and neurogenesis. Conceptually it sits alongside other neurotrophic strategies discussed in this work: the multi-factor brain hydrolysate Cerebrolysin (which has clinical-stage data), direct TrkB agonists such as 7,8-DHF, and BDNF gene therapy — but unlike several of those, P21 has no human trials at all. Its preclinical reach is notably broad: Alzheimer's disease, cognitive aging, normal-cognition enhancement, prenatal/developmental rescue in a Down syndrome model, and prevention of age-related macular degeneration in the retina. That breadth is its appeal; the complete absence of human data, the unresolved mechanism, and the one in-vivo failure are its limits — which is why Dr. Seeds frames it as a fascinating research peptide that is not ready for use.

> **⚠ P21 is a PRECLINICAL research compound with ZERO human clinical trials, no established human dose, no human pharmacokinetics, and no human safety data — all evidence is from rodent and in-vitro models. It is NOT FDA-approved. Dr. Seeds explicitly recommends AGAINST current human/clinical use and states he has no human data to share. (He notes some groups outside the US are reportedly exploring an intranasal formulation, but this does not change its preclinical, unproven status.) Nothing in this guide should be read as endorsement of human use.**

SECTION 2 · MODES OF ACTION AND MECHANISMS

P21's mechanism is distinctive and still only partly resolved. It does not work the way its parent molecule does: it does not bind the CNTF receptor or activate the receptor complex responsible for CNTF's toxicity. Instead, the working model is competitive inhibition of LIF signaling, paired with upregulation of BDNF and a downstream cascade that reduces tau pathology and promotes neurogenesis and synaptic repair — almost entirely demonstrated in vitro and in rodents.

Primary Pathway: Competitive LIF Inhibition

Leukemia inhibitory factor (LIF) suppresses the formation of neural progenitor cells from stem cells. In cell culture, P21 competitively inhibits LIF-induced STAT3 phosphorylation by roughly 30%, with dose-dependent effects detectable as low as 0.1 nM and statistical significance by ~10 nM. Crucially, P21 does NOT directly bind the CNTF receptor (CNTFRα) — a fundamental departure from full-length CNTF — and the exact target is still under study (proposed possibilities include neutralizing anti-CNTF activity or direct LIF antagonism). The net effect is relief of LIF-mediated suppression, allowing neural progenitor proliferation.

BDNF / TrkB / PI3K / Akt / GSK-3β Cascade

P21 increases BDNF transcription and protein in the hippocampus and cortex. BDNF activates its TrkB receptor, which drives the PI3K/Akt pathway; Akt then phosphorylates GSK-3β at Ser9 (an inhibitory phosphorylation), reducing GSK-3β activity and, in turn, tau hyperphosphorylation. P21 also engages PLC/PKC and MEK/ERK signaling and raises the pCREB/CREB ratio — and because CREB drives BDNF, this sets up a positive-feedback loop. The molecular fingerprint in animal studies: upregulated BDNF, TrkB, p-Akt, p-Ser9-GSK-3β, and pCREB; reduced phospho-tau at the AT8, PHF1, and 12E8 sites; and increased synaptic markers (MAP2, synaptophysin, synapsin I, PSD-95) and glutamate-receptor subunits (NMDA: NR1, NR2A, NR2B; AMPA: GluR1, GluA2/3). An honest caveat Dr. Seeds flags: whether the BDNF increase is a direct effect of P21 or a secondary consequence of LIF inhibition remains debated.

Downstream Neurobiological Effects (Animal)

Across 3xTg-AD mice and aged rats, the downstream effects are consistent: a roughly 4-fold increase in DCX+ neurogenesis in AD mice at 9 months (exceeding wild-type); broad synaptic-plasticity restoration; anti-amyloid action that reduces soluble Aβ40/Aβ42 by decreasing its generation rather than enhancing clearance (about −20% in CA1 and −40% in subiculum); an approximately 50% reduction in phospho-tau (AT8/PHF1) at 18 months; neuroprotection (fewer Fluoro-Jade C^{+} degenerating neurons and markedly higher survival — 87% vs 41% of vehicle at week 71); and an anti-inflammatory effect reducing microgliosis (Iba-1) and astrogliosis (GFAP) in both brain and retina.

Why P21 Avoids CNTF's Toxicities

The therapeutic rationale rests on what P21 does NOT do. Full-length CNTF's side effects (anorexia, muscle loss, hyperalgesia, cramps, nausea, weight loss) stem from activating the systemic IL6Rα–LIFRβ–gp130 receptor complex. P21 neither binds CNTFRα nor activates that complex, and accordingly produced no CNTF-like side effects across all tested rodent doses and durations. The important caveat: this advantage is demonstrated only in rodents, and human receptor pharmacology may differ.

> **Key mechanistic point: P21 is a small CNTF-derived peptide that does NOT bind the CNTF receptor or activate the toxic IL6Rα–LIFRβ–gp130 complex. Its working mechanism is competitive LIF inhibition (relieving suppression of neural progenitors) plus BDNF upregulation feeding TrkB → PI3K/Akt → inhibitory GSK-3β phosphorylation → reduced tau, with a pCREB–BDNF positive-feedback loop. Downstream (in animals): ~4× neurogenesis, reduced amyloid (via lower generation) and tau, synaptic repair, and a large survival benefit. The mechanism is coherent but only partly resolved and entirely preclinical — and whether BDNF upregulation is direct or secondary to LIF inhibition is still debated.**

A Note on the CDKL5 In-Vivo Failure

One result deserves special attention because it qualifies the whole picture. In a 2024 study of CDKL5-deficiency disorder (Mottolese et al.), P21 worked in vitro — in CDKL5-knockout cells it restored proliferation, survival, and neuritic length and normalized GSK-3β phosphorylation — but FAILED in vivo: in CDKL5-knockout mice it did not increase BDNF, produced no neuroanatomical improvement, and gave only limited behavioral benefit. The likely interpretation is that the CNTF/LIF-mediated response P21 depends on is disrupted in the CDKL5-null brain environment. The implications are important: P21's mechanism is not universal across neurological disorders, it appears context-dependent (requiring an intact pathway to work), and — as Dr. Seeds stresses — this failure must be disclosed whenever P21's broad applicability is discussed. It is a useful reminder that strong results in some models do not guarantee benefit in others.

SECTION 3 · POINTS OF CLINICAL RELEVANCE

- **The defining tension.** Broad, consistent, even disease-modifying-looking preclinical data — but zero human trials, and Dr. Seeds recommends against use.

P21's animal data are unusually broad and consistent, including signals that look disease-modifying (tau and amyloid reduction, large neurogenesis and survival effects). But there are no human clinical trials, no established human dose, pharmacokinetics, or safety data, and Dr. Seeds is explicit that this is a peptide to study rather than use right now. Preclinical breadth is not human readiness, and that must be stated plainly.

- **A CNTF that avoids CNTF's toxicities.** The core design achievement is decoupling benefit from harm.

Full-length CNTF failed clinically (in ALS and obesity) because of anorexia, muscle loss, cramps, and hyperalgesia driven by the IL6Rα–LIFRβ–gp130 complex. P21 does not bind CNTFRα or activate that complex and showed none of those effects in rodents — the central reason it is of interest. The caveat: this is shown only in rodents, and human receptor pharmacology may differ.

- **Disease-modifying-looking signals in AD models.** Tau, amyloid, neurogenesis, and survival all move favorably.

In 3xTg-AD mice, P21 reduced phospho-tau by ~50%, lowered soluble amyloid by reducing its generation (a mechanism distinct from anti-amyloid antibodies), increased DCX+ neurogenesis ~4-fold, restored cognition, and improved survival to 87% vs 41% of vehicle. These are the findings that make P21 compelling — but they are in mice.

- **Breadth well beyond Alzheimer's.** Aging, normal cognition, prenatal Down syndrome, and the retina.

P21 enhanced cognition and neurogenesis in aged rats and even in normal mice, rescued developmental delays and memory in a prenatally treated Down syndrome model (crossing the placenta), and prevented AMD-like retinal pathology (photoreceptor and RPE protection, reduced retinal inflammation, blocked sub-retinal VEGF). Dr. Seeds highlights the macular-degeneration and prenatal-neurodevelopment threads as especially interesting directions.

- **The CDKL5 in-vivo failure matters.** The mechanism is context-dependent, not universal.

P21 succeeded in CDKL5-knockout cells but failed in CDKL5-knockout mice (no BDNF increase, no neuroanatomical benefit), suggesting its LIF/CNTF-dependent action requires an intact pathway. This tempers the "broadly applicable" narrative and must be disclosed alongside the positive models.

- **The mechanism is still partly unresolved.** Key questions remain open.

P21 does not bind CNTFRα, its exact receptor/target is not defined, BBB penetration is inferred rather than directly measured, and whether the BDNF increase is direct or secondary to LIF inhibition is unsettled. The story is coherent but incomplete.

- **No human anything.** No trials, no PK, no dose, no human safety.

There is no human efficacy, pharmacokinetic, dosing, or safety data for P21, and rodent data should not be assumed to translate. Any human use is unsupported and, per Dr. Seeds, to be avoided at present.

SECTION 4 · DOSING, DELIVERY, AND CURRENT-USE POSTURE

There is NO established human dose for P21 and NO human pharmacokinetic data. The doses below are from rodent studies and are NOT translatable to humans. Dr. Seeds's explicit guidance is that P21 should be AVOIDED for human/clinical use at present — he states he has no human dosing data to share. This section documents the preclinical record for reference only; it is not a dosing protocol.

Preclinical Dosing (Rodent — Not Translatable)

Model	Route	Dose	Duration
3xTg-AD mice (adult onset)	Oral (in diet)	60 nmol/g feed	6–18 months
Aged rats (22–24 mo)	Oral gavage	500 nM (~289 µg/kg/day)	88 days
Wild-type mice (8–10 mo)	SC pellets	25 nM/day	35 days
Ts65Dn mice (Down syndrome)	Oral (in diet)	200 nmol/g feed	Prenatal E8 → PND21
CDKL5-KO mice	Oral (in diet)	60 nmol/g feed	P21 → P90 (70 days)
3xTg-AD mice (early dev.)	Oral (in diet)	Not specified	Birth → PND120

Pharmacokinetics & Delivery (Rodent / In Vitro)

- Small and penetrant: MW 578.3 Da; the adamantylated glycine improves lipophilicity, GI stability, and (inferred) CNS entry.
- Plasma half-life >3 hours in mice; >90% intact after 30 minutes in artificial gastric juice and 100% intact after 2 hours in artificial intestinal fluid — supporting oral delivery in rodents.
- Primary rodent delivery was dietary admixture (60–200 nmol/g feed); gavage and slow-release SC pellets were also used; P21 crosses the placental barrier (Down syndrome model).
- Critical gaps: BBB permeability was inferred from behavioral outcomes, not directly measured; human oral bioavailability, half-life, volume of distribution, protein binding, drug interactions, and pregnancy/lactation safety are all uncharacterized.

Current-Use Posture & Development Status

Unlike several other peptides in this series, there is no established clinical-practice use of P21 to describe, and Dr. Seeds's guidance is to avoid it at present. Development is at the preclinical/IND stage (Phanes Biotech, for Alzheimer's disease), with human trials pending and no IND/NDA filed as of 2024. Dr. Seeds notes anecdotally that some groups outside the US are reportedly exploring an intranasal formulation rather than oral delivery, but he has no data to share and does not endorse use. Any combination ideas in the literature (e.g., pairing with direct TrkB agonists such as 7,8-DHF, or shared GSK-3β targeting with agents like lithium or tideglusib) are purely mechanistic rationale, with no human or combination data.

SECTION 5 · EVIDENCE PROFILE

Preclinical Evidence by Model (All Animal / In Vitro)

Study / Model	Key Finding
Li 2010 — normal C57Bl6 mice	Improved recognition/spatial memory; increased neurogenesis and synaptic markers (normal cognition)
Blanchard 2010 — normal adult mice	Enhanced DG neurogenesis and plasticity; improved spatial reference memory
Kazim 2014 — 3xTg-AD mice	Reduced p-tau and soluble Aβ; increased BDNF and p-Ser9-GSK-3β; restored neurogenesis; improved cognition
Baazaoui 2017 — 3xTg-AD mice	~4× DCX+ neurogenesis; Aβ −20%/−40%; tau ~50% reduction; survival 87% vs 41%
Bolognin 2014 — aged rats	Restored neurogenesis, BDNF/TrkB/pCREB, synaptic markers, MWM (not to young levels)
Kazim 2017 — Ts65Dn (Down syndrome)	Crosses placenta; rescued developmental delays and memory; BDNF +2×; pCREB up
Liu 2019 — AMD model (mice + rats)	Prevented photoreceptor/RPE degeneration, retinal inflammation, tau/Aβ, sub-retinal VEGF
Wei 2020/2021 — early postnatal AD	Prenatal-to-early treatment prevented Alzheimer-like behavior and synaptic dysfunction
Mottolese 2024 — CDKL5 deficiency	In vitro positive; IN VIVO FAILED (no BDNF increase, no neuroanatomical benefit)

What Can and Cannot Be Confirmed

Can confirm	Cannot confirm
Sequence/MW; oral and GI stability in rodents	Any human efficacy, dose, or safety (no trials)
Competitive LIF inhibition in vitro; no CNTFRα binding	The exact molecular target/receptor for P21
Broad neurogenic/anti-tau/anti-amyloid effects in animals	Human pharmacokinetics or direct BBB quantification
Large survival and cognition benefits in AD mice	Whether benefits translate to humans or to all disorders (CDKL5 in-vivo failure)

Can confirm	Cannot confirm
No CNTF-like side effects in rodents (up to 18 mo)	Human safety, carcinogenicity, drug interactions, pregnancy/lactation

Critical Evidence Gaps

- Zero human clinical trials; no human dose, pharmacokinetics, or safety data of any kind.
- BBB permeability inferred from behavior, not directly quantified; exact receptor/target undefined.
- No genotoxicity/carcinogenicity studies, no primate toxicokinetics, no long-term data beyond 18 months.
- CDKL5 in-vivo failure shows the mechanism is context-dependent, not universal.
- Observed weight gain in rodents (without increased food intake) has uncharacterized metabolic implications.

SECTION 6 · CLINICAL CONSIDERATIONS

Regulatory & Development Status

P21 is not FDA-approved and is a preclinical-stage research compound. It is being developed by Phanes Biotech for Alzheimer's disease, but remains at the preclinical/IND stage with no IND or NDA filed as of 2024 and no human trials completed. There is no approved or validated human use, and Dr. Seeds's position is that it should be avoided clinically at present.

Safety Profile

All safety data are from rodents, where the profile was favorable: no weight loss, tumors, or pain behaviors over durations up to 18 months; no changes in grooming, posture, clasping reflex, body temperature, anxiety (elevated plus-maze), or motor function; and, importantly, none of the CNTF-associated toxicities. One ambiguous finding is a possible increase in body weight without a change in food intake, whose metabolic implications are unclear. None of this establishes human safety: there is no human data whatsoever, no genotoxicity/carcinogenicity testing, no primate toxicokinetics, and no information beyond 18 months — and the CDKL5 in-vivo failure raises mechanistic questions in its own right.

Evidence Integrity & the CDKL5 Result

Practitioners weighing P21 should hold the CDKL5 result alongside the positive models: in-vitro success did not translate to in-vivo benefit in the CDKL5-null brain, indicating the mechanism is context-dependent and not universally applicable. This is not a data-integrity problem (as with a retraction) but a genuine biological limitation that constrains how broadly P21's promise can be generalized, and Dr. Seeds is explicit that it must be disclosed in any balanced discussion.

Contraindications & Cautions

Because P21 has no human use case at present, "contraindications" are effectively superseded by the broader point that it is not ready for human use. If the published preclinical considerations are extrapolated prudentially, the unknowns most relevant to any future human evaluation would include the uncharacterized weight-gain/metabolic effect, the complete absence of pregnancy/lactation and pediatric safety data (notwithstanding the prenatal animal work), unknown drug interactions, and the unproven assumption that the rodent freedom from CNTF

toxicity will hold in humans. None of these are established human contraindications — they are reasons the compound is not clinically usable yet.

Patient Selection & Practitioner Posture

The responsible posture here is unusually simple and Dr. Seeds states it plainly: P21 is not for clinical use at this time. It is a genuinely interesting neurotrophic peptide — with notable promise in Alzheimer's biology, BDNF/tau/amyloid effects, and age-related macular degeneration — and a valuable lesson in how a CNTF fragment might preserve benefit while shedding toxicity. But with no human trials, no established dose or pharmacokinetics, no human safety data, an unresolved mechanism, and a documented in-vivo failure, the appropriate stance is to follow its development, not to use it. If a practitioner nonetheless encounters it, full disclosure of its preclinical-only status and Dr. Seeds's recommendation against use is essential.

Monitoring

There is no human monitoring framework for P21 because there is no validated human use. Were it ever to enter supervised human study, the preclinical record suggests the parameters that would need attention — cognitive/functional endpoints, BDNF and tau/amyloid biomarkers, weight and metabolic measures (given the rodent weight-gain signal), and standard safety labs — but these are research-design considerations, not clinical monitoring recommendations.

SECTION 7 · A FINAL NOTE

P21 is one of the most scientifically interesting peptides in the neuroprotection group and, at the same time, the clearest example of a compound that is not ready for use. It is a small, CNTF-derived, orally available, CNS-penetrant peptide engineered to capture ciliary neurotrophic factor's pro-neurogenic benefit while shedding the IL6Rα–LIFRβ–gp130-driven toxicities that doomed full-length CNTF in human trials. Mechanistically it works by competitively inhibiting LIF and upregulating BDNF, driving a TrkB → PI3K/Akt → GSK-3β cascade that lowers tau, plus a pCREB–BDNF feedback loop — producing, in animals, a roughly 4-fold rise in neurogenesis, reduced amyloid and tau, broad synaptic repair, and a striking survival benefit, with parallel promise in cognitive aging, normal cognition, a prenatal Down syndrome model, and age-related macular degeneration.

And yet the honest accounting is unambiguous. Every result is preclinical — there are no human trials, no established dose, no human pharmacokinetics, and no human safety data — the BBB penetration is inferred rather than measured, the exact molecular target is undefined, and whether the BDNF increase is direct or secondary to LIF inhibition is unsettled. The CDKL5 in-vivo failure shows the mechanism is context-dependent rather than universal. Development sits at the preclinical/IND stage with no IND or NDA filed.

For the practitioner, the posture follows directly and is stated plainly by Dr. Seeds: P21 should be avoided for clinical use at present. It is a peptide to learn from — a proof of concept that a neurotrophic fragment can decouple benefit from toxicity, and a promising candidate for Alzheimer's, neurodevelopmental, and retinal disease — and a peptide to follow as it moves toward human trials, but not one to use today. The most responsible contribution a clinician can make is to understand its biology, disclose its preclinical-only status honestly, and watch for the human data that does not yet exist.

> **Bottom line: P21 (P021) is a small CNTF-derived neurotrophic peptide (Ac-DGGLAG-NH_2, MW 578.3 Da) that does NOT bind CNTFRα or trigger CNTF's toxic receptor complex, acting instead via competitive LIF inhibition and BDNF upregulation (TrkB→PI3K/Akt→GSK-3β→less tau). In animals it produced ~4× neurogenesis, ~50% tau**

reduction, lower amyloid (via reduced generation), broad synaptic repair, an 87% vs 41% survival benefit, and promise across aging, Down syndrome, and macular degeneration — with no CNTF-like side effects. BUT it is ENTIRELY preclinical: zero human trials, no established dose/PK/safety, an inferred (not measured) BBB, an undefined target, and a documented CDKL5 in-vivo failure. NOT FDA-approved. Dr. Seeds explicitly recommends AGAINST current use — a compelling research peptide to follow, not to use.

Selected References & Source Note

1. Li B et al. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett. 2010;584(15):3359-3365. [Animal Study]
2. Blanchard J et al. Beneficial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis, neuronal plasticity, and spatial memory in mice. J Alzheimers Dis. 2010;21(4):1185-1195. [Animal Study]
3. Kazim SF et al. Disease-modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple-transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014;71:110-130. [Animal Study]
4. Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017;9(1):45. [Animal Study]
5. Baazaoui N, Iqbal K. Prevention of amyloid-beta and tau pathologies, associated neurodegeneration, and cognitive deficit by early treatment with a neurotrophic compound. J Alzheimers Dis. 2017;58(1):215-230. [Animal Study]
6. Kazim SF et al. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome. Sci Rep. 2017;7:45561. [Animal Study]
7. Iqbal K et al. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener. 2016;11(1):50. [Review]
8. Liu Y et al. Inhibition of AMD-like pathology with a neurotrophic compound in aged rats and 3xTg-AD mice. Front Aging Neurosci. 2019;11:309. [Animal Study]
9. Wei W et al. Neurotrophic treatment initiated during early postnatal development prevents the Alzheimer-like behavior and synaptic dysfunction. J Alzheimers Dis. 2021;82(2):631-646. [Animal Study]
10. Baazaoui N, Iqbal K. Alzheimer's disease: challenges and a therapeutic opportunity to treat it with a neurotrophic compound. Biomolecules. 2022;12(10):1409. [Review]
11. Mottolese N et al. Effects of a CNTF small-molecule peptide mimetic in an in-vitro and in-vivo model of CDKL5 deficiency disorder. J Neurodev Disord. 2024;16(1):65. [Animal Study / In Vitro — in-vivo FAILURE]
12. Wei W et al. Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. Alzheimers Res Ther. 2020;12(1):102. [Animal Study]